文献速递免疫规划卫生政策与健康促进

将男孩纳入新加坡全国学校人乳头瘤病毒疫苗接种规划的成本效果建模分析

Impact of including boys in the national school-based human papillomavirus vaccination programme in Singapore: A modelling-based cost-effectiveness analysis.
PubMed 文献 · Vaccine · 2023-02-14

研究采用世界卫生组织支持的Papillomavirus Rapid Interface for Modelling and Economics模型,评估新加坡13岁男孩纳入学校HPV疫苗接种规划的成本效果。在80%疫苗覆盖率下,改用 gender-neutral 接种策略用二价或九价疫苗每出生队列可分别避免30例和34例HPV相关癌症。3%贴现率下不具有成本效果,1.5%贴现率下二价疫苗可能具有成本效果,增量成本效果比为每获得一个QALY需19007新加坡元。

要点

  • 研究对象为新加坡13岁儿童,比较性别中立与仅女孩接种HPV疫苗的成本效果。
  • 80%覆盖率下,二价和九价疫苗每出生队列分别避免30例和34例HPV相关癌症。
  • 3%贴现率下性别中立接种不具有成本效果,1.5%贴现率下二价疫苗可能具有成本效果,ICER为每QALY 19007新加坡元。

核心结论

  • 从医疗保健角度,3%贴现率下将男孩纳入学校HPV疫苗接种规划不具有成本效果,但1.5%贴现率下使用二价疫苗可能具有成本效果。
  • 研究结果提示需要邀请专家详细审查新加坡性别中立HPV疫苗接种规划的成本效果。
  • 还应考虑药物许可、可行性、性别公平、全球疫苗供应和全球消除/根除疾病趋势等问题。

研究设计与样本

  • 研究采用世界卫生组织支持的Papillomavirus Rapid Interface for Modelling and Economics模型,从医疗保健角度进行成本效果分析。
  • 模型评估为13岁儿童接种HPV疫苗相关的成本和质量调整生命年(QALY)。
  • 癌症发病率和死亡率来自当地数据,并根据80%疫苗覆盖率下不同人群亚组的预期直接和间接疫苗保护进行调整。

主要发现

  • 在80%疫苗覆盖率下,改用性别中立的二价疫苗接种规划每出生队列可避免30例HPV相关癌症(95%不确定性区间[UI]:20-44)。
  • 在80%疫苗覆盖率下,改用性别中立的九价疫苗接种规划每出生队列可避免34例HPV相关癌症(95% UI:24-49)。
  • 3%贴现率下,性别中立HPV疫苗接种规划不具有成本效果。
  • 1.5%贴现率下,改用性别中立的二价疫苗接种规划可能具有成本效果,增量成本效果比为每获得一个QALY需19007新加坡元(95% UI:10164-30633)。

关键数值与推荐

  • 二价疫苗性别中立规划每出生队列避免30例HPV相关癌症(95% UI:20-44)。
  • 九价疫苗性别中立规划每出生队列避免34例HPV相关癌症(95% UI:24-49)。
  • 1.5%贴现率下二价疫苗性别中立规划的增量成本效果比为每QALY 19007新加坡元(95% UI:10164-30633)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Globally, gender-neutral Human Papillomavirus (HPV) vaccination programmes are gaining traction. Although cervical cancer remains the most prevalent, other HPV-related cancers are increasingly recognised as important, especially among men who have sex with men. We assessed if including adolescent boys in Singapore's school-based HPV vaccination programme is cost-effective from the healthcare perspective. We adapted a World Health Organization-supported model, Papillomavirus Rapid Interface for Modelling and Economics, and modelled the cost and quality-adjusted life years (QALY) associated with vaccinating 13-year-olds with the HPV vaccine. Cancer incidence and mortality rates were obtained from local sources and adjusted based on the expected direct and indirect vaccine protection for various population subgroups at an 80 % vaccine coverage. Moving to a gender-neutral vaccination programme with a bivalent or nonavalent vaccine could avert 30 (95 % uncertainty interval [UI]: 20-44) and 34 (95 % UI: 24-49) HPV-related cancers per birth cohort, respectively. At a 3 % discount rate, a gender-neutral vaccination programme is not cost-effective. However, with a 1.5 % discount rate, which puts more value on long-term health gains from vaccination, moving to a gender-neutral vaccination programme with the bivalent vaccine is likely cost-effective, with an incremental cost-effectiveness ratio of SGD$19 007 (95 % UI: 10 164-30 633) per QALY gained. The findings suggest the need to engage experts to examine, in detail, the cost-effectiveness of gender-neutral vaccination programmes in Singapore. Issues of drug licensing, feasibility, gender equity, global vaccine supplies, and the global trend towards disease elimination/eradication should also be considered. This model provides a simplified method for resource-strapped countries to gain a preliminary estimate of the cost-effectiveness of a gender-neutral HPV vaccination programme before investing resources for further research.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Wahab MT, Tan RKJ, Cook AR, et al. Impact of including boys in the national school-based human papillomavirus vaccination programme in Singapore: A modelling-based cost-effectiveness analysis. Vaccine. 2023. PMID: 36797100. doi:10.1016/j.vaccine.2023.02.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。